Education
About Us
Working with TipRanks
Follow Us
Nova Eye Medical (ELXMF)
OTHER OTC:ELXMF
Earnings Data
Report Date
Aug 27, 2026TBA (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
―Last Year’s EPS
>-0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong operational momentum: record quarterly sales, robust U.S. growth (27% YoY; 40% CAGR over six halves), high procedure volumes (~17,000 last 12 months; ~180,000 total), industry-leading sales productivity (~$2M per rep) and improving operating cash flow (positive in December). At the same time, management flagged meaningful risks and constraints: small current market share (~3.9%), geographic volatility (notably China), dependence on the U.S., the need to carefully pace sales rep expansion to protect revenue per rep, working capital unpredictability, and a broad guidance range. On balance the call projects positive execution and growth momentum but acknowledges operational and market-access risks that could impact near-term predictability.Company Guidance
Strong Revenue Growth and Record Quarter
Record sales in the December quarter; last 12 months sales up ~24% year-over-year overall, with management reporting continuing momentum into January.
Robust U.S. Performance and High CAGR
United States revenue growth of ~27% over the last 12 months and a reported 40% compound annual growth rate (CAGR) in the U.S. over the last six halves.
Procedure Volume and Market Traction
Run rate of ~17,000 procedures in the last 12 months and ~180,000 iTrack procedures performed globally to date, indicating sustained clinical adoption.
High Sales Productivity
Sales productivity reported as nearly $2.0 million revenue per sales rep in the last quarter, described as industry-leading and a key driver of operating results.
Regulatory Approvals, Reimbursement and Clinical Evidence
Device is FDA-approved and reimbursed by U.S. Centers for Medicare & Medicaid Services; management emphasized robust registry/real-world clinical evidence with a first peer-reviewed registry paper expected imminently.
Improving Operating Cash Flow and Operational Capacity
Management reported positive operating cash flow in the December quarter and a month-over-month cash increase in December; capacity to scale production from an FDA-approved Fremont factory; improvement in cost of goods sold with volume.
ELXMF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ELXMF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 27, 2025 | $0.10 | $0.10 | 0.00% |
Feb 25, 2025 | $0.10 | $0.10 | 0.00% |
Feb 22, 2024 | $0.10 | $0.10 | 0.00% |
Feb 28, 2023 | $0.10 | $0.10 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Nova Eye Medical (ELXMF) report earnings?
Nova Eye Medical (ELXMF) is schdueled to report earning on Aug 27, 2026, TBA (Confirmed).
What is Nova Eye Medical (ELXMF) earnings time?
Nova Eye Medical (ELXMF) earnings time is at Aug 27, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ELXMF EPS forecast?
Currently, no data Available